# Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Source: https://onco.cc/trials/nct07007312/  
OnCo record `nct07007312` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ziftomenib, Venetoclax, Azacitidine, Daunorubicin and Cytarabine in acute myeloid leukaemia, run by Kura Oncology, Inc., now recruiting.

## Summary

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML is a phase 3 interventional study registered as NCT07007312 by Kura Oncology, Inc., with 1300 participants planned, started 2025-09-26 and due to reach its primary completion in 2031-11. Interventions recorded: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin and Cytarabine (Ara-C).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07007312
- Phase: 3
- Setting: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
- Sponsor: Kura Oncology, Inc.
- Enrolled: 1300

## Sources

- ClinicalTrials.gov NCT07007312: https://clinicaltrials.gov/study/NCT07007312

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- companies: [Kura Oncology](https://onco.cc/companies/kura-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct07007312.json